The discovery of new cholesteryl ester transfer protein inhibitors

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 5, 2001, Pages 602-613

  Sikorski, J A ^a   Connolly, D T ^a  

^a AtheroGenics Inc   (United States)

Author keywords

Atherosclerosis; CETP; Cholesteryl ester; Cholesteryl ester transfer protein; Coronary artery disease; HDL cholesterol elevation; Neutral lipid transfer

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,2' DITHIODIPYRIDINE; 6,6' DITHIODINICOTINIC ACID; ACETYL COENZYME A; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; AROMATIC COMPOUND; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID METHYL ESTER; PALMITOYL COENZYME A; PROPANOL; PROPIONYL COENZYME A; PROTEIN INHIBITOR; SC 66960; SC 67201; SC 71952; TETRALIN DERIVATIVE; TORCETRAPIB; U 617; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; PEPTIDE;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; NONHUMAN; RABBIT; REVIEW; ANIMAL; BIOSYNTHESIS; CHEMISTRY; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTICHOLESTEREMIC AGENTS; CARRIER PROTEINS; HUMAN; LIPOPROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034812097     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Plasma cholesteryl ester transfer protein
2. 1999 George Lyman Duff memorial lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis
3. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein
4. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study
5. Range of serum cholesterol values in the population developing coronary artery disease
6. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
7. Roles of plasma lipid transfer proteins in reverse cholesterol transport
8. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis
9. Cholesteryl ester transfer protein and atherosclerosis
10. Pros and cons of inhibiting cholesteryl ester transfer protein
11. Relationship of the cholesteryl ester transfer protein (CETP) to atherosclerosis
12. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipo-proteinemia
13. The antiatherogenic role of high-density lipoprotein cholesterol
14. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency
15. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
16. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein
17. Blood Feud
18. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
19. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study
20. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein
21. Cholesteryl ester transfer protein as a potential therapeutic target to improve the HDL to LDL cholesterol ratios
22. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein
23. Physical and kinetic characterization of recombinant human cholesteryl ester transfer protein
24. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: Involvement of a critical cysteine
25. Cloning and sequencing of human cholesteryl ester transfer protein cDNA
26. Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides, and cholesteryl sulfate
27. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
28. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F
29. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity
30. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma
31. Kinetics and inhibition of lipid exchange catalyzed by plasma cholesteryl ester transfer protein (lipid transfer protein)
32. Inactivation of cholesteryl ester transfer protein by cysteine modification
33. Bis(2-(acylamino)phenyl) disulfides, 2(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein
34. Cholesteryl myristate. Structures of the crystalline solid and mesophases
35. Low molecular weight CETP inhibitors: A new approach for the treatment of hypoalphalipoproteinemia?
36. Pfizer optimistic for the future, December 11 2000
37. Stereoselective Mukaiyama-Michael/Michael/Aldol Domino cyclization as the key step in the synthesis of pentasubstituted arenes: An efficient access to highly active inhibitors of cholesteryl ester transfer protein (CETP)
38. Discovery of chiral N,N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein
39. Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluoro-3-amino-2-propanols
40. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein